“…As the maximum tolerated dose was revealed to be 110 mg/m 2 in patients without hepatocarcinoma, a high incidence of adverse events (e.g., 100% all grades and 38% grade 3 among all patients), such as fever, fatigue, back pain, nausea, diarrhea, anorexia, and vomiting, was found among patients with liver cancer receiving treatment with MRX34 (10-50 mg/m 2 , i.v., biweekly) who required palliative management with dexamethasone premedication. Nevertheless, MRX34 did exhibit antitumor activity among patients with refractory advanced solid tumors (Beg et al, 2017;Hong et al, 2020), offering valuable insight into the development of miRNA therapeutics.…”